Abstract Null mutations in GRN are associated with frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP). However, the influence of progranulin (PGRN) deficiency in neurodegeneration is largely unknown. In neuroblastoma cells, silencing of GRN gene causes significantly reduced cell survival after serum withdrawal. The following observations suggest that alterations of the CDK4/6/retinoblastoma protein (pRb) pathway, secondary to changes in PI3K/Akt and ERK1/2 activation induced by PGRN deficiency, are involved in the control of serum deprivation-induced apoptosis: (i) inhibiting CDK4/6 levels or their associated kinase activity by sodium butyrate or PD332991 sensitized control SH-SY5Y cells to serum deprivation-induced apoptosis without affecting survival of PGRN-deficient cells; (ii) CDK4/6/pRb seems to be downstream of the PI3K/Akt and ERK1/2 signaling pathways since their specific inhibitors, LY294002 and PD98059, were able to decrease CDK6-associated kinase activity and induce death of control SH-SY5Y cells; (iii) PGRN-deficient cells show reduced stimulation of PI3K/Akt, ERK1/2, and CDK4/6 activities compared with control cells in the absence of serum; and (iv) supplementation of recombinant human PGRN was able to rescue survival of PGRN-deficient cells. These observations highlight the important role of PGRN-mediated stimulation of the PI3K/Akt-ERK1/2/CDK4/6/pRb pathway in determining the cell fate survival/death under serum deprivation.
Introduction
The term frontotemporal lobar degeneration (FTLD) refers to a group of progressive brain rare diseases, which involve shrinkage of specific areas of the brain that regulate behavior, personality, and language. The onset of symptoms usually occurs before the age of 60 years, accounting for 5-10 % of dementia patients [1, 2] .
The neuropathological hallmark of FTLD is the degeneration of frontal and temporal lobes, as well as the accumulation of protein inclusions in neuronal and glial cells [3] . FTLD subtypes have been established depending on the proteins found in these inclusions. The main subtypes are FTLD-tau and FTLD-TDP for microtubule-associated protein tau (MAPT) and FTLD-TDP for ubiquitinated transactive response DNA-binding protein 43 (TDP-43) positive inclusions, respectively [4] [5] [6] . A large subset of FTLD-TDP patients has been identified to harbor loss-of-function mutations (including null mutations) in the gene-encoding progranulin (GRN) [7, 8] and a smaller number of mutations in the valosincontaining protein (VCP) gene [9] , transactive response (TAR) DNA-binding protein-43 (TARDBP ) [10] , sequestome1/p62 (SQSTM1) [11] , and ubiquilin-2 (UBQLN2) [12] . A C9ORF72 hexanucleotide expansion in chromosome 9 has been described to be responsible for familial frontotemporal dementia overlapping with motor neuron disease (FTD-MND) cases and amyotrophic lateral sclerosis (ALS) [13, 14] . GRN mutations are dominantly inherited and the disease mechanism is postulated to be haploinsufficiency, as most GRN mutations lead to an approximately 50 % reduction in PGRN levels [15] [16] [17] .
PGRN is a 593 amino acid, 86 kDa cysteine rich protein containing a signal peptide and 7.5 repeats of highly conserved granulin motifs [18] . PGRN is widely distributed [19] , including the central nervous system (CNS) [20] . Previous research has suggested that PGRN may function as an autocrine neuronal growth factor involved in the inflammatory neuronal repair process in the CNS [21] . PGRN has been reported to promote neuronal survival in culture [22] , though the degree of this effect is controversial [23] . The effects of PGRN deficit in the CNS have been also studied in GRN knockdown neuronal cells [24, 25] and knockout mice (GRN−/−). The GRN-silenced neuronal cells were shown to display some of the phenotypic characteristics of the disease such as increased cytosolic accumulation of TDP-43 and increased vulnerability of neurons to normally sublethal insults [25] . Increased caspase activation and decreased TDP-43 solubility were also found in GRN KD cortical neurons [26] . On the other hand, GRN−/− mice develop ubiquitin-positive aggregates and phosphorylated TDP-43, similar to FTLD-TDP patients [27, 28] . Thus, it seems that GRN KD neuronal cells is a suitable experimental model to study FTLD-TDP associated with loss-of-function GRN mutations.
Previous work from this laboratory highlighted the role of the CDK6/retinoblastoma protein (pRb) pathway in controlling cell fate survival/death of peripheral cells from carriers of a loss-of-function GRN mutation, c.709-1G>A [29] . In this work, we have addressed the issue as to whether PGRN deficiency also modulates this cascade and eventually cell survival in a neuroblastoma cell line. For this purpose, we used a stable clone of SH-SY5Y cells in which GRN expression was knocked down by a vector-based shRNA approach [24] . Compared with control cells, survival of GRN KD SH-SY5Y cells was severely reduced in serum-free medium. Our results suggest that alterations in the CDK4/6/pRb pathway, secondary to changes in the activity of the PI3K/Akt and ERK1/2 pathways induced by PGRN deficiency, are involved in the control of serum deprivation-induced apoptosis.
Materials and Methods

Materials
All components for cell culture were obtained from Invitrogen (Barcelona, Spain). LY294002 and PD98059 were obtained from Calbiochem (Darmstadt, Germany). Progranulin (human recombinant) was obtained from Enzo (Zandhoven, Belgium). Elastase from human leukocytes, epidermal growth factor (EGF), the 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide reactive (MTT), and the inhibitor of histone deacetylases, sodium butyrate (SB), were obtained from Sigma-Aldrich (Tres Cantos, Spain). The inhibitor of CDK6/CDK4-associated kinase activity, PD332991, was obtained from Pfizer (Gronton, CT, USA). The 4,6-diamino-2-phenylindole (DAPI) and insulin were obtained from Life Technologies (Eugene, OR, USA). Antibodies used in this study are listed in Table 1 . Poly(vinylidene fluoride) (PVDF) membranes were purchased from Merk Millipore (Billerica, MA, USA). The enhanced chemiluminiscence (ECL) system was from Amersham (Uppsala, Sweden). Other reagents were of molecular biology grade.
GRN Knockdown Neuroblastoma SH-SY5Y Cell Lines
Stable GRN knockdown neuroblastoma SH-SY5Y cells (clone #207) was a generous gift from Drs. Joselin and Wu from the Center for Genetic Medicine (Northwestern University, Chicago, IL, USA). GRN knockdown was achieved by using pSUPERIOR RNAi construct as previously described [24] . The target sequence of 19 nucleotides targeted against nucleotides 207-226 (#207) of the human GRN messenger RNA (mRNA) was designed. The 64-nt short-hairpin RNA sense and antisense primer sequences were 5′ -gatccccggccactcctgcatctttattcaagagataaagatgcaggagtggcctttttggaaa-3′ and 5′agcttttccaaaaaggccactcctgcatctttatctcttgaataaag atgcaggagtggccggg-3′.
The sense and antisense primer pairs were annealed and ligated into the pSUPERIOR vector (OligoEngine) according to the manufacturer's instructions. The vector control was also stably introduced into SH-SY5Y cells to generate the control cell line. 
Assessment of Apoptosis and Caspases Activity
Apoptosis was characterized by chromatin condensation/fragmentation, as determined by cell fixation followed by 4,6-diamidino-2-phenylindole (DAPI) staining and fluorescence microscopy examination. The activation of executive caspases was investigated using the Vybrant® FAM Caspase-3 and 7 Kit (Invitrogen, Carlsbad, CA, USA) including fluorochrome-labeled inhibitors of caspases (FLICA) reagent that is retained within the cell, if bound to the active caspase molecule. Control and GRN KD SH-SY5Y were resuspended in 300 μl of DMEM containing 10 μl of FLICA reagent and incubated in 5 % CO 2 at 37°C for 60 min. The cells were then washed and suspended in wash buffer provided by the kit. The samples were analyzed on the flow cytometer.
Immunoblotting Analysis
Cells were harvested, washed in PBS, and then lysed in icecold lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 50 mM NaF, 1 % Nonidet P-40), containing 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl flouride (PMSF), 1 mM sodium pyrophosphate, and protease inhibitor Complete Mini Mixture (Roche, Mannheim, Germany). The 20 to 50 μg of protein from cell extracts were fractionated on a sodium dodecyl sulfate (SDS) polyacrylamide gel and transferred to PVDF membrane. The membranes were then blocked with Bovine Serum Albumin (BSA) (Sigma) or dry milk and incubated with primary antibodies as indicated in Table 1 . The release of cytochrome c from the mitochondria was assessed after cell fractioning to get cytosolic and crude mitochondrial extracts as described [31] , using the ApoTrack™ Cytochrome c Apoptosis Antibody Cocktail. Signals from the primary antibodies were amplified using species-specific antisera conjugated with horseradish peroxidase (Bio-Rad) and detected with a chemiluminiscent substrate detection system ECL (Amersham). The antibody specificity was checked by omitting the corresponding primary antibody in the incubation medium. Protein band densities were quantified using Image J software (National Institutes of Health, Bethesda, MD, USA) after scanning the images with a GS-800 densitometer from Bio-Rad and normalized by those of β-actin or α-tubulin. When indicated, cytosolic or mitochondrial proteins were normalized by GAPDH and C-V-α or PDH-E1-α, respectively.
Quantitative Real-Time PCR Total RNA was extracted from cell cultures using Trizol® reagent (Invitrogen, Alcobendas, Madrid, Spain). RNA yields were quantified spectrophotometrically and RNA quality was checked by the A260/A280 ratio and on a 1.2 % agarose gel to determine the integrity of 18S and 28S ribosomal RNA. RNA was then treated with DNase I Amplification Grade (Invitrogen, Alcobendas, Madrid, Spain). One microgram was reverse transcribed with the Superscript III Reverse Transcriptase kit (Invitrogen, Alcobendas, Madrid, Spain). Quantitative real-time polymerase chain reaction (PCR) was performed in triplicates using TaqMan® Universal PCR MasterMix No Amperase UNG (Applied Biosystems, Alcobendas, Madrid, Spain) reagent according to the manufacturer's protocol. Primers were designed using the Universal Probe Library for Human (Roche Applied Science, Madrid, Spain) and used at a final concentration of 20 μM. The sequences of the forward and reverse primers used are the following: for GRN, 5′-tctgtagtctgagcgctaccc-3′ and 5′-agggtccacatggtctgc-3′; for β-actin, 5′-ccaaccgcgagaagatga-3′ and 5′-ccagaggcgtacagggatag-3′. Real-time quantitative PCR was performed in the Bio-Rad iQ5 system using a thermal profile of an initial 5-min melting step at 95°C followed by 40 cycles at 95°C for 10 s and 60°C for 60 s. Relative messenger RNA (mRNA) levels of the genes of interest were normalized to β-actin expression using the simplified comparative threshold cycle delta-delta CT method (2 -[ΔCT GRN -ΔCT Actin] ).
Statistical Analysis
Statistical analyses were performed on GraphPad Prism 5 for Macintosh (La Jolla, CA, USA). All the statistical data are presented as mean±standard error of the mean (SEM). Statistical significance was estimated by analysis of variance (ANOVA) followed by the Bonferroni's test for multiple comparisons. Differences were considered significant at a level of p<0.05.
Results
GRN Knockdown Increased the Vulnerability of Cells to Serum Deprivation
To study the effects of PGRN deficiency on cell survival, we took advantage of stable GRN knockdown SH-SY5Y (GRN KD cells), generated in Dr. Wu lab with a pSUPERIOR RNAi construct containing the target sequence corresponding to nucleotide sequences 207 to 226 specific for human GRN gene [24] . As shown in Fig. 1a , b, a considerable decrease in GRN mRNA and protein content was observed in KD cells compared with control SH-SY5Y cells expressing the empty vector. After serum deprivation, we found marked differences in cell survival between control and GRN KD cells as assessed by the MTT assay. While in control cultures, a large number of cells still survive 4 days after serum deprivation; in PGRNdeficient cells there was an important reduction in cell viability from the first day (Fig. 1c) .
Extracellular PGRN Protects GRN KD Cells from Serum Deprivation-Induced Cell Death
To explore whether PGRN is able to protect SH-SY5Y cells from serum withdrawal, we treated GRN KD cells with exogenous recombinant human progranulin (rhPGRN) for 3 days. Figure 2a shows that the addition of exogenous rhPGRN was able to increase the percentage of survival of PGRN-deficient cells up to the levels found in control cells. The effect of rhPGRN disappeared when it was previously degraded by elastase (Fig. 2a) . As shown in Fig. 2b , left panel, incubation of rhPGRN with 0.1 U/ml of elastase for 3 h was sufficient to completely degrade PGRN. In addition, the stability of extracellular rhPGRN in the cell culture was checked by collecting conditioned medium from control cells after 72 h of serum starvation, incubated with rhPGRN in the absence or in the presence of elastase. As shown in Fig. 2b right panel, PGRN seems to be remarkably stable in the neuronal medium. In contrast, extracellular PGRN was significantly degraded by exogenous elastase (Fig. 2b) . Taken together, these results suggest that the pro-survival effect of added rhPGRN is most likely due to the full-length protein rather than to granulin peptides.
Serum Withdrawal Induces Apoptosis
Cell death induced by serum deprivation showed characteristics of apoptosis. First of all, the examination of serumdeprived control and GRN KD cells after DAPI staining with a fluorescence microscopy revealed the abundance of chromatin condensation fragments (arrows) in the nuclei of GRN KD cells (Fig. 3a) . On the other hand, fluorescent cell distribution using FLICA green fluorescent probe indicates higher activity of executive caspases 3 and 7 ( Fig. 3b ) in PGRNdeficient cells when compared with control cells, as FLICA binds irreversibly to these enzymes when activated [32] , thus increasing the fluorescence signal in apoptotic cells. Moreover, we observed that serum deprivation induced a higher release of cytochrome c to the cytosolic compartment in PGRN-deficient cells than in control cells (Fig. 4) . These results suggest the activation of the intrinsic (mitochondrial activated) pathway.
Role of CDK4/6/pRb Pathway on Cell Survival
We had previously shown that PGRN deficit altered the activity of CDK4/6-associated kinase and survival of peripheral cells from FTLD-TDP patients bearing a GRN null mutation [29] . On these grounds, we were interested in evaluating the role of the CDK4/6/pRb pathway in the survival/death of control and PGRN-depleted neuroblastoma cell lines under serum deprivation conditions. Western blot analysis revealed a significant higher content of CDK4 and CDK6 in control cells, compared with KD cells. Consequently, an elevated CDK activity, as determined by the higher phosphorylation status of the retinoblastoma protein (pRb), was also observed in control cells (Fig. 5a ). To investigate if CDK4/6 levels determine the ability of the GRN knockdown cells to survive in serum-deprived medium, we inhibited CDK4/6 activity, either with an inhibitor of histone deacetylases (HDAC), such as sodium butyrate (SB), to blunt the CDK4 and CDK6 mRNA expression or with the small molecule PD332991 (Pfizer) that specifically inhibits the CDK4/6-associated kinase activity. Incubation of control cells with SB-reduced CDK4 and CDK6 protein levels ( Fig. 5a upper panel) . Both 4 Enhanced release of cytochrome c to the cytosol in serumdeprived GRN KD neuroblastoma SH-SY5Y cells. Control and GRN KD cells were serum deprived for 72 h. Cell lysates were fractionated to isolate cytoplasmic and crude mitochondria. The presence of cytochrome c in cytosolic and mitochondrial fractions was assessed by Western blot analysis using the ApoTrack™ antibody cocktail, which demonstrates the purity of the fractions and loading. A representative blot is shown. Densitometric analyses are presented below. The data represent the mean±SEM of the mitochondrial and cytosolic cytochrome c for four independent experiments. Single asterisk indicating p<0.05 and double asterisk indicating p<0.01 are significantly different from control cells SB and PD332991 inhibited CDK4/6-associated kinase activity as indicated by the decrease in the phosphorylation status of pRb (Fig. 5a, lower panel) . In these conditions, control cells died as PGRN-depleted cells did (Fig. 5b) .
Signaling Pathways Involved in the Serum Deprivation-Mediated Stimulation of Cell Death
Two signaling cascades have emerged as major players in the control of survival/death of many different cells: the mitogenactivated protein kinase (MAPK) and the phosphoinositide-3 kinase (PI3K) pathways [33] [34] [35] . Both pathways are more active in control than in GRN KD cells as indicated by the higher phosphorylation status of Akt and ERK1/2 (Fig. 6a) . The potential participation of these signaling pathways in controlling cell survival was analyzed by using pharmacological inhibitors. We tested the effects of PD98059, inhibitor of MEK1/2, the upstream activator of ERK1/2, and LY294002, inhibitor of PI3K. We confirmed the effect of these inhibitors on the phosphorylation status of their respective kinases (Fig. 6b) . LY294002 inhibited the Akt phosphorylation without affecting ERK1/2 phosphorylation status, whereas PD98059 decreased ERK1/2 phosphorylation but did not modify Akt phosphorylation (Fig. 6a) . As shown in Fig. 6b , both LY294002 and PD98059 sensitized control cells to cell death induced by serum deprivation. Under these experimental conditions, control cells underwent apoptosis as did GRN KD cells. These findings suggest that PGRN deficiency impaired the activation of these two survival pathways. Inhibition of PI3K/Akt by LY294002, as well as the inhibition of ERK1/2 phosphorylation by PD98059, decreased the content of CDK6 in control cells to levels found in GRN KD cells (Fig. 7) . Both inhibitors were also effective in decreasing the phosphorylation of pRb protein (Fig. 7) . Taken together, these results suggest that cell fate (survival or death) ultimately Exogenous PGRN Normalizes the PI3K/Akt and ERK1/2 Activity in GRN KD Cells
We evaluated next whether the addition of rhPGRN to the incubation medium was able to increase PI3K/Akt and ERK1/ 2 activities. As shown in Fig. 8 , rhPGRN restored the phosphorylation status of both Akt (Fig. 8a , left panel) and ERK1/2 (Fig. 8a , right panel) in PGRN-deficient cells. In addition, it is shown that rhPGRN normalized CDK4 and CDK6 levels and pRb phosphorylation in GRN KD cells, reaching similar to control cells (Fig. 8b) .
Effects of EGF and Insulin on Survival of GRN KD Neuronal Cells
Since PGRN deficiency seems to result in decreased PI3K/ Akt and ERK1/2 activities, we sought to evaluate if GRN KD cells could be rescued from death induced by serum deprivation in the presence of other physiologically relevant activators of these pathways such as EGF or insulin [36, 37] . As expected, both EGF and insulin increased the levels of pAkt and pERK1/2 ( Fig. 9 upper panel) . Under these conditions, GRN KD cells were able to survive in the absence of serum ( Fig. 9 lower panel) .
Discussion
Loss-of-function GRN mutations are casually associated with FTLD; however, how the PGRN deficit induces specific neuronal death remains to be determined. In this work, we have addressed the question as to whether knocking down the GRN gene in human neuroblastoma cells SH-SY5Y determines the cell fate, survival/death, in response to a cell stressor like serum withdrawal. In addition, we have investigated the influence of PGRN deficiency on the PI3K/Akt and ERK1/2 signaling pathways. Our results indicate that PGRN-deficient cells are more vulnerable to serum deprivation. The GRN KD cells show features of apoptosis, as increased activation of executive caspases and cytochrome c released from the mitochondria compared with control cells. Addition of rhPGRN to the culture medium of GRN KD cells protects them from the serum withdrawal-induced apoptosis, suggesting that PGRN acts primarily through an extracellular mechanism. Interestingly, the effect of exogenous PGRN is most likely due to the full-length protein, rather than to granulin peptides.
In agreement with previous reports from this laboratory that revealed an important role for CDK4/6/pRb pathway in controlling survival of lymphoblasts from carriers of a loss-offunction GRN mutation [29] , we observed in GRN KD neuroblastoma cells significant changes in the levels of CDK4 and CDK6 and the phosphorylation status of pRb protein. Increased signaling through CDK4/6/pRb pathway was associated with a survival advantage in both lymphoblasts and neuroblastoma cells. However, PGRN deficiency induced opposites changes in CDK4/6/pRb and cell resistance to serum deprivation in lymphoblasts and SH-SY5Y cells. Thus, it seems that PGRN influences cell fate survival/death in cell type-specific manner. Exogenous rhPGRN was able to increase cell viability in GRN KD neuroblastoma cells to levels similar to control cells. In a similar way, rhPGRN was able to restore the "normal" cell response to serum stimulation or withdrawal [29, 38] , by blunting the enhanced proliferative activity of PGRN-deficient lymphoblasts or sensitizing cells to apoptosis in the absence or serum. The resistance of FTLD lymphoblasts towards a proapototic stimuli such as serum withdrawal may be explained by the tumor-like features of these cell lines, which it is believed reflects, at the systemic level, the proposed relationship between cellular stress and unscheduled cell cycle entry observed in susceptible neurons in neurodegenerative disorders [39, 40] . Thus, the possibility should be considered that the reduced CDK4/6/pRb activity, induced by PGRN deficiency in neuroblastoma cell lines could represent an attempt to blunt cell cycle progression of vulnerable neurons under conditions of chronic stress.
The involvement of CDK4/6/pRb in the control of the response of SH-SY5Y cells to serum deprivation is further supported by the fact that survival of control cells is reduced in the presence of specific inhibitors of either CDK4 and CDK6 expression levels or the CDK4/6-associated kinase activity such as SB or PD332991, respectively. The effects of these two drugs on survival of SH-SY5Y cells are in consonance with the reported effect of PD332991 on myeloma, increasing the cell sensitivity to bortezomib-induced apoptosis [41] and with the observation that knockdown of CDK6 enhanced the susceptibility of glioma cells to chemotherapy [42] . The fact that these drugs did not affect survival of PGRN-deficient cells, suggest a threshold for CDK4/6-associated kinase [43] . Moreover, an anti-apoptotic role for CDK/pRb has been suggested, since a correlation between pRb loss and induction of apoptosis appears to occur in as pRb −/− null mice [44] . Nonetheless, our results contrast with other works suggesting a role of increased CDK6 activity in neuronal cell death [45, 46] , and neuroprotection through the inhibition of specific CDKs has been demonstrated [47, 48] . Thus, it seems that activation of CDK/pRb can have a pro-or antiapoptotic role in neuronal cells depending perhaps on the cell status or the nature of the cell stressor.
Analysis of the molecular signaling changes during serum deprivation in GRN knockdown cells revealed significant differences in the level of phosphorylated Akt and ERK1/2 compared with control cells. GRN KD cells showed impaired activation of both pathways. Treatment of control cells with the PI3K/Akt inhibitor LY294002 or the ERK1/2 inhibitor PD98059 induced significant apoptosis to levels similar to GRN KD cells. Therefore, it seems that PGRN may protect against apoptosis induced by serum withdrawal by activating the PI3K/Akt and ERK1/2 survival pathways. Indeed, we could observe the activating effects of rhPGRN in PI3K/Akt and ERK1/2 in PGRN-deficient neuroblastoma cells. This observation is in consonance with the previous reports showing the involvement of PGRN in activating these signaling pathways in a number of cell types [49, 50] and in the reported anti-apoptotic effect of PGRN in primary neurons [51, 22, 52] . Moreover, activation of the PI3K/Akt and ERK1/2 pathways by EGF or insulin was sufficient to support survival of GRN KD cells in the absence of serum.
Our data suggest that CDK4/6 is a target of both PI3K/Akt and ERK1/2 signaling pathways since the effects of LY294002 or PD98059 inducing apoptosis in control cells are accompanied by a significant decrease in CDK4 and CDK6 levels. In a similar way, ablation of Akt was shown to downregulate CDK4 and CDK6 expression [53, 54] . Thus, it seems that PGRN-dependent PI3K/Akt and ERK1/2 activation plays a critical role as mediator of cell survival by regulating the activity of the CDK4/6/pRb pathway. The proposed scenario is represented schematically in Fig. 10 . The nature of the link between PGRN deficiency, PI3K/Akt and ERK1/2 signaling, and CDK4/6/pRb activity remains to be resolved. Changes in signaling molecules and/or receptors can occur in PGRN deficiency, for example, alterations in circulating cytokines were detected in serum of FTLD patients carriers of a lossof-function GRN mutation [55] , and changes in Wnt signaling had been found in cells from FTLD patients [56, 57] . This issue is currently under investigation in our laboratory.
Together, our data indicate a neuroprotective role for PGRN and provide further support for the premise that chronic PGRN deficiency in FTLD results in reduced survival signaling and increased neuronal vulnerability to cellular stressors, leading to increased rates of neuronal cell death. Treatment with exogenous PGRN or alternatively with activators of the PI3K/Akt and ERK1/2 pathways may be useful for prevention and treatment of FTLD-TDP associated to PGRN haploinsufficency. 
